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Background:  Studies have not evaluated medical versus surgical management of severe aortic stenosis (AS) in patients with a low gradient (< 30 
mm Hg mean gradient), a moderate gradient (30-40 mm Hg mean gradient), and a severe gradient (> 40 mm Hg mean gradient) and normal left 
ventricular ejection fraction (LVEF).
Methods:  We searched an outpatient faculty cardiology practice database for patients with severe AS (aortic valve area < 1.0 cm2) by the 
continuity equation and normal LVEF (> 50%) with no other significant valvular heart disease. Patients were divided into 3 groups: group 1 (low-
gradient), group 2 (moderate-gradient), and group 3 (severe-gradient) severe AS. We investigated the incidence of death, aortic valve replacement 
(AVR), and death or AVR in the 3 groups. Kaplan-Meier survival curves for medical versus surgical management were constructed for the 3 groups.
Results:  Groups 1,2, and 3 included 94, 87, and 67 patients, respectively. Follow up was 60 months, 55 months, and 45 months for groups 1, 
2, and 3, respectively (p not significant). Death occurred in 52 of 94 group 1 patients (55%), in 34 of 87 group 2 patients (39%), and in 26 of 67 
group 3 patients (39%) (p not significant). AVR occurred in 22 of 94 group 1 patients (23%), in 46 of 87 group 2 patients (53%), and in 33 of 67 
group 3 patients (49%) (p <0.0001 for group 1 versus 2 and p = 0.0003 for group 1 versus 3). Stepwise Cox regression analysis showed that AVR 
(hazard ratio = 0.30, p < 0.0001) and mitral annular calcium (hazard ratio = 2.3, p = 0,001) were significant independent risk factors for time 
to mortality. Kaplan-Meier survival curves for patients treated medically versus AVR showed that patients in all 3 groups who underwent AVR had 
significantly greater survival (p = 0.002 by log-rank test for group 1; p = 0.0002 by log-rank test for group 2; and p = 0.011 by log-rank test for 
group 3).
Conclusions:  In conclusion, among patients with normal LVEF and severe AS, overall survival did not differ for those with low-gradients, moderate-
gradients, or severe-gradients. Patients with low-gradients are significantly less likely to undergo AVR. Survival is significantly improved with AVR, 
regardless of gradient.
